Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841601 | 0.92 | TRPA1 (0.39) | TRPA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4843678 | 0.92 | TRPA1 (0.38) | TRPA1RORCCA12CA1CA2 | |
| SCHEMBL4842910 | 0.91 | TRPA1 (0.37) | TRPA1RORCCA12CA1CA2 | |
| SCHEMBL4837466 | 0.91 | TRPA1 (0.40) | TRPA1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4839140 | 0.90 | ALDH1A1 (0.39) | TRPA1RORCCA12CA1CA2 | |
| SCHEMBL4841040 | 0.87 | MAPT (0.40) | TRPA1RORCALDH1A1TP53MAPT | |
| SCHEMBL4833601 | 0.84 | CA12 (0.40) | TRPA1CA12CA1CA2CA9 | |
| SCHEMBL4841989 | 0.83 | TRPA1 (0.37) | TRPA1CA12CA1CA2CA9 | |
| SCHEMBL4843300 | 0.82 | TRPA1 (0.39) | TRPA1CA12CA1CA2CA9 | |
| SCHEMBL4842551 | 0.82 | ALDH1A1 (0.41) | TRPA1RORCALDH1A1RAB9ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TRPA1 368/4885PDE4A 1988/4885PDE4B 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.